Briggs D C, Vaughan R W, Welsh K I, Myers A, duBois R M, Black C M
Department of Immunogenetics, Guy's Hospital, London, UK.
Lancet. 1991 Sep 14;338(8768):661-2. doi: 10.1016/0140-6736(91)91235-m.
75 systemic sclerosis patients were independently tested for pulmonary fibrosis, autoantibodies, and MHC class II genes. 24 of 42 (57%) patients with pulmonary fibrosis had either HLA DR3/DRw52a or anti-Scl-70 vs 2 of 33 (6%) patients without pulmonary fibrosis. The presence of DR3/DRw52a or anti-Scl-70 gives a relative risk of 16.7 for the development of pulmonary fibrosis in a patient with scleroderma--a risk substantial enough to require careful monitoring of these patients and treatment at an early stage of disease.
对75例系统性硬化症患者独立进行了肺纤维化、自身抗体和MHC II类基因检测。42例（57%）肺纤维化患者中，24例具有HLA DR3/DRw52a或抗Scl - 70，而33例无肺纤维化患者中只有2例（6%）具有这些特征。DR3/DRw52a或抗Scl - 70的存在使硬皮病患者发生肺纤维化的相对风险为16.7——这一风险足够大，需要对这些患者进行仔细监测并在疾病早期进行治疗。
